GSK vs. REGN, BMY, ZTS, VRTX, SNY, TAK, PFE, ABT, NVS, and AZN
Should you be buying GSK stock or one of its competitors? The main competitors of GSK include Regeneron Pharmaceuticals (REGN), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Sanofi (SNY), Takeda Pharmaceutical (TAK), Pfizer (PFE), Abbott Laboratories (ABT), Novartis (NVS), and AstraZeneca (AZN). These companies are all part of the "pharmaceutical preparations" industry.
Regeneron Pharmaceuticals (NASDAQ:REGN) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking.
Regeneron Pharmaceuticals received 677 more outperform votes than GSK when rated by MarketBeat users. Likewise, 66.56% of users gave Regeneron Pharmaceuticals an outperform vote while only 57.04% of users gave GSK an outperform vote.
In the previous week, Regeneron Pharmaceuticals had 2 more articles in the media than GSK. MarketBeat recorded 19 mentions for Regeneron Pharmaceuticals and 17 mentions for GSK. GSK's average media sentiment score of 0.74 beat Regeneron Pharmaceuticals' score of 0.54 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.
83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 8.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Regeneron Pharmaceuticals currently has a consensus price target of $976.41, indicating a potential upside of 7.61%. Given GSK's stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than GSK.
Regeneron Pharmaceuticals has a net margin of 30.14% compared to Regeneron Pharmaceuticals' net margin of 16.24%. Regeneron Pharmaceuticals' return on equity of 51.45% beat GSK's return on equity.
Regeneron Pharmaceuticals has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.
GSK has higher revenue and earnings than Regeneron Pharmaceuticals. GSK is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Regeneron Pharmaceuticals beats GSK on 13 of the 18 factors compared between the two stocks.
Get GSK News Delivered to You Automatically
Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
